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Abstract
Sandwich-cultured hepatocytes (SCH) are used commonly to investigate hepatic transport protein-
mediated uptake and biliary excretion of substrates. However, little is known about the disposition
of endogenous bile acids (BAs) in SCH. In this study, four endogenous conjugated BAs common
to rats and humans [taurocholic acid (TCA), glycocholic acid (GCA), taurochenodeoxycholic acid
(TCDCA), and glycochenodeoxycholic acid (GCDCA)], as well as two BA species specific to
rodents (α- and β-tauromuricholic acid; α/β TMCA), were profiled in primary rat and human
SCH. Using B-CLEAR® technology, BAs were measured in cells+bile canaliculi, cells, and
medium of SCH by LC-MS/MS. Results indicated that, just as in vivo, taurine-conjugated BA
species were predominant in rat SCH, while glycine-conjugated BAs were predominant in human
SCH. Total intracellular BAs remained relatively constant over days in culture in rat SCH. Total
BAs in control (CTL) cells+bile, cells, and medium were approximately 3.4, 2.9, and 8.3-fold
greater in human than in rat. The estimated intracellular concentrations of the measured total BAs
were 64.3 ± 5.85 μM in CTL rat and 183 ± 55.6 μM in CTL human SCH, while medium
concentrations of the total BAs measured were 1.16 ± 0.210 μM in CTL rat SCH and 9.61 ± 6.36
μM in CTL human SCH. Treatment of cells for 24 h with 10 μM troglitazone (TRO), an inhibitor
of the bile salt export pump (BSEP) and the Na+-taurocholate cotransporting polypeptide (NTCP),
had no significant effect on endogenous BAs measured at the end of the 24-h culture period,
potentially due to compensatory mechanisms that maintain BA homeostasis. These data
demonstrate that BAs in SCH are similar to in vivo, and that SCH may be a useful in vitro model
to study alterations in BA disposition if species differences are taken into account.
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Introduction
Sandwich-cultured hepatocytes (SCH)—primary hepatocytes cultured in a sandwich
configuration between layers of collagen or extracellular matrix—are commonly employed
as an in vitro model to examine the hepatic disposition and metabolism of compounds and to
determine mechanisms of hepatotoxicity. When cultured in conventional monolayer, cells
dedifferentiate over time and rapidly lose hepatocyte-specific functions (Dunn et al. 1991).
However, when cultured in a sandwich configuration, hepatocytes continue to synthesize
and secrete hepatocyte-specific compounds such as albumin, urea, transferrin and
fibrinogen; meanwhile, the synthesis and efflux of BAs into the culture medium in SCH
remain relatively steady for up to 42 days in culture (Shibukawa et al. 1995). SCH begin to
repolarize hours after plating, cytochrome P450 (CYP450) enzymes are expressed, transport
proteins traffic to their proper membrane domains and are functional over days in culture,
and over time adjacent cells form intact, bile-canaliculi-like structures sealed by tight
junctions into which endogenous and exogenous compounds may be secreted (LeCluyse et
al. 1994; Liu et al. 1999a; Liu et al. 1999b; Liu et al. 1999c). B-CLEAR® technology allows
quantification of intracellular accumulation and bile canalicular excretion of endogenous
and exogenous compounds by modulating the integrity of these tight junctions through the
presence or absence of Ca2+ and Mg2+.
Recent research suggests that interference with normal BA transport may be an important
mechanism of drug- and xenobiotic-induced hepatotoxicity (Pauli-Magnus and Meier 2006)
through the inhibition of BA transport proteins or the retrieval of transporters from the
hepatocyte plasma membrane (Zollner and Trauner 2008). The vectorial, active hepatic
uptake and efflux of BAs are mediated by a number of transport proteins that are expressed
on the basolateral (sinusoidal) or apical (canalicular) membrane domains. On the basolateral
membrane, Na+-taurocholate cotransporting polypeptide (NTCP/Ntcp) is primarily
responsible for the Na+-dependent uptake of conjugated BAs from the blood, while isoforms
of organic anion transporting polypeptide (OATP/Oatp) take up conjugated and
unconjugated BAs and other organic anions; OATP/Oatp isoforms also may function as bi-
directional transporters (Trauner and Boyer 2003). On the apical membrane, BSEP and
multidrug resistance-associated protein 2 (MRP2/Mrp2) efflux monovalent and divalent
BAs, respectively, into the bile canaliculi (Keppler et al. 1999; Keppler and Konig 2000).
Inhibition of transport proteins may mediate liver injury by increasing the intracellular
accumulation of potentially toxic compounds (parent drug/xenobiotic and/or metabolites), as
well as endogenous BAs, which can cause toxicity through detergent effects on cellular
membranes, mitochondrial dysfunction, and ultimately cellular apoptosis or necrosis
(Delzenne et al. 1992; Desmet 1995; Gores et al. 1998; Pauli-Magnus et al. 2005).
A number of drugs inhibit rat and/or human Bsep/BSEP-mediated biliary secretion of TCA
in vitro including cyclosporin A, glibenclamide, rifampin, bosentan, ritonavir, saquinavir,
efavirenz, and troglitazone (TRO) (Fattinger et al. 2001; Funk et al. 2001a; Kemp et al.
2005; McRae et al. 2006; Pauli-Magnus and Meier 2006; Stieger et al. 2000). TRO, the first
thiazolidinedione drug introduced to treat type II diabetes, was removed from the market
because of hepatotoxicity, but preclinical safety testing did not predict toxicity in humans.
Studies have demonstrated that TRO, and particularly its major metabolite, troglitazone
sulfate (TS), inhibit BA transport (Funk et al. 2001a; Funk et al. 2001b; Kemp et al. 2005;
Preininger et al. 1999). TRO-induced hepatotoxicity observed in humans may not have been
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observed in rats during preclinical testing due to species differences in the composition of
the BA pools, and differential effects on the hepatobiliary transport of BAs.
Drug-induced changes in the intra- and/or extracellular disposition of individual BAs may
be indicators of the hepatotoxic potential of a compound. The goals of this study were to
profile endogenous BAs in primary rat and human SCH in order to compare species
differences between rat and human in the disposition of BAs common to both, to determine
whether inhibition of BA transport proteins mediated by TRO treatment causes the
intracellular accumulation of endogenous BAs, and to elucidate whether distinct changes in
intra- and extracellular accumulation and biliary excretion of individual BA species occur
such that a particular BA would be a marker for transport inhibition. In order to accomplish
these goals, the mass of TCA, GCA, TCDCA, and GCDCA accumulated in cells+bile
canaliculi, cells, and medium of SCH were quantified by LC-MS/MS following 24 h
treatment with vehicle or 10 μM TRO. The accumulation of α/β TMCA was also included
in rat SCH. Furthermore, intracellular and biliary concentrations of BAs were calculated
using estimated cell volumes for human and rat hepatocytes.
Materials and Methods
Chemicals
TRO was purchased from Biomol (Plymouth Meeting, PA). Dexamethasone, Hanks’
balanced salt solution (HBSS) premix, and HBSS modified (without calcium chloride,
magnesium sulfate, phenol red, and sodium bicarbonate) premix were purchased from
Sigma-Aldrich (St. Louis, MO). Collagenase (type I, class I) was obtained from
Worthington Biochemical (Freehold, NJ). Dimethyl sulfoxide (DMSO) was purchased from
Fisher Scientific (Fairlawn, NJ). GIBCO brand Fetal bovine serum, insulin, and Dulbecco’s
modified Eagle medium (DMEM) were obtained from Invitrogen (Carlsbad, CA). ITS™+
Premix (insulin, transferrin, selenium) and BD Matrigel™ Basement Membrane Matrix
were purchased from BD Biosciences (Palo Alto, CA). The d8 TCA was purchased from
Martrex, Inc. (Minnetonka, MN), d4 TCA was purchased from Toronto Research Chemicals,
Inc. (Toronto, Ontario, Canada), and all other deuterated BAs were purchased from CDN
Isotopes, Inc. (Pointe-Claire, Quebec, Canada). The bile acids α- and β-TMCA were
purchased from Steraloids, Inc. (Newport, RI). All other chemicals and reagents were of
analytical grade and were readily available from commercial sources.
Hepatocyte isolation and culture
Hepatocytes were isolated from male Wistar rats (250-300 g; Charles River Laboratories,
Inc., Raleigh, NC) using a two-step collagenase perfusion method previously described (Liu
et al., 1998; Annaert et al., 2001). Rats were maintained on a 12-hr light/dark cycle with free
access to water and standard rodent chow, and were allowed to acclimate for at least 5 days
before experimentation. The Institutional Animal Care and Use Committee of the University
of North Carolina at Chapel Hill approved all procedures. Human hepatocytes were obtained
from CellzDirect (Durham, NC) pre-plated on 6-well BioCoat plates with collagen type I
substratum (BD Biosciences, Bedford, MA). Donor information is listed in Table 1.
Rat hepatocytes were seeded at a density of 1.75 × 106 cells per well on 6-well BioCoat™
plates in 1.5 ml DMEM supplemented with 5% (v/v) fetal bovine serum, 10 μM insulin, and
1 μM dexamethasone, 2 mM L-glutamine, 1% (v/v) MEM non-essential amino acids, 100
units penicillin G sodium and 100 μg streptomycin sulfate. Cells were incubated at 37°C,
5% CO2 in a humidified incubator and allowed to attach for 2 h, after which time the
medium was aspirated to remove unattached cells, and replaced with fresh medium. Twenty-
four hours later, on day 1 of culture, rat and human hepatocytes were overlaid with BD
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Matrigel™ basement membrane matrix at a concentration of 0.25 mg/mL in ice-cold
DMEM supplemented with 1% (v/v) ITS™+ Premix, 0.1 μM dexamethasone, 2 mM L-
glutamine, 1% (v/v) MEM non-essential amino acids, 100 units penicillin G sodium and 100
μg streptomycin sulfate. Rat and human hepatocytes were cultured for up to 3 and 6 more
days, respectively, to allow for the formation of canalicular networks between cells. Culture
medium was replaced daily.
Determination of BAs in cells+bile and cells of untreated rat SCH over days in culture
At 24, 48, 72, and 96 h post-seeding, 1 ml aliquots of culture medium were collected from
each of 6 wells of rat SCH and stored at <−70°C until analysis. The remaining 0.5 ml of the
culture medium was aspirated and duplicate wells were rinsed briefly with 1.5 ml/well of
warmed HBSS containing Ca2+ (cells+bile), while two wells were rinsed with HBSS
without Ca2+ (cells only), and the wash buffer was aspirated. Following the wash, 1.5 ml of
HBSS with or without Ca2+ was added again to wells, and cells were incubated for 4 min at
37°C. Incubation of SCH with Ca2+-containing buffer maintained the tight junctions
between cells so that the bile canalicular structures formed between cells remained intact.
Incubation of cells in Ca2+-free buffer disrupted the tight junctions and opened the bile
canalicular structures between cells, allowing the contents to be washed away. Following
incubation, the HBSS was aspirated from each well and plates were sealed and stored at <
−70°C until analysis.
Determination of cholesterol 7-alpha-hydroxylase (Cyp7a1) protein expression in cells of
untreated rat SCH over days in culture
At 24, 48, 72, and 96 h post-seeding, culture medium was aspirated from duplicate wells and
cell lysates were collected in 400 μl lysis buffer containing 1% sodium dodecyl sulfate
(SDS), 1 mM ethylenediaminetetraacetic acid (EDTA), and protease inhibitors (Halt™
Protease Inhibitor Cocktail, Thermo Scientific, Rockford, IL). Protein concentrations were
determined using the Pierce BCA™ (bicinchoninic acid) Protein Assay Kit (Thermo
Scientific, Rockford, IL). Whole-cell lysates (45 μg) were resolved on a Nu-PAGE® 10%
Bis-Tris Mini gel (Life Technologies™, Carlsbad, CA) and proteins were transferred to an
Immobilon™ polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, MA). The
membrane was blocked in 5% milk in Tris-buffered saline with Tween-20 (TBS-T) for two
hours at room temperature (RT). Membranes were incubated for two hours at RT with
Cyp7a1 antibody (Abgent, San Diego, CA) and β–actin (C4, Chemicon, San Francisco,
CA). Following incubation with HRP-tagged secondary antibodies, chemiluminescence was
detected using SuperSignal® West Dura Extended Duration Substrate (Thermo Scientific,
Rockford, IL) and a Bio-Rad Chemidoc XRS imaging system. Densitometry analysis was
performed using QuantityOne v.4.5.2 software (Bio-Rad Laboratories, Hercules, CA).
Accumulation of BAs in cells+bile, cells, and culture medium of rat and human SCH
On day 3 (rat) or 6 (human) of culture, medium was aspirated from each well of SCH and
replaced with 1.5 ml medium containing vehicle (0.1% DMSO) or 10 μM TRO. Cells were
incubated at 37°C for an additional 24 h. Following incubation, 1 ml aliquots of the culture
medium were collected for analysis of BAs in the medium, and the remaining 0.5 ml was
aspirated. Triplicate wells were briefly rinsed 2 times with 2 ml per well of warmed HBSS
with or without Ca2+. After the washes, 2 ml of HBSS with or without Ca2+ was added, and
cells were incubated at 37°C for 4 min. Following the 4-min incubation, the HBSS was
aspirated, and plates were stored at <−70°C until analysis. Human and rat SCH were
handled identically except that human SCH were treated on day 6 of culture, and samples
were collected 24 h later on day 7.
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Sample preparation for LC-MS/MS analysis of BAs in cell lysates
Calibration standards and quality controls (QCs) utilized in the quantification of unknown
samples were prepared in a biological matrix containing endogenous BAs. Deuterated BA
equivalents were utilized in the preparation of these calibration standards and QCs to avoid
any variable background contribution from these endogenous compounds. Quantification of
all BAs utilized an internal standard method wherein deuterated TCA (d4-TCA) was added
during sample preparation to all standards, QCs, and unknown samples for all BAs. The
specific stable isotope d8-TCA was utilized to prepare the calibration standards and QCs
supporting the measurement of both TCA and α/β TMCA in the unknown samples. Ten
microliters of deuterated BAs [d8-taurocholic acid (d8-TCA), d4-glycocholic acid (d4-GCA),
d4-taurochenodeoxycholic acid (d4-TCDCA), and d4-glycochenodeoxycholic acid (d4-
GCDCA)] solutions in methanol were added to previously frozen, untreated rat and human
SCH plates. The final concentration range for rat cell lysate analysis was 0.5 - 100 pmol/
well, and for human cell lysate analysis was 0.5 – 50 pmol/well for taurine conjugates and
10 – 1000 pmol/well for glycine conjugates. Lysis solution (750 μl; 70:30 methanol:water
[v/v] containing 25 nM d4-TCA as an internal standard) were added to each well of study
plates and to plates containing standards. Plates were shaken on a rotating plate shaker (Lab-
Line Instruments Model 4625) at a speed of 500 rpm for 15 min. The total contact time of
the lysis solution with cells, prior to filtration, was ~20–30 min. The cell lysates were
transferred to a Whatman 96-well Unifilter Plate (Whatman, Florham Park, NJ) with 25 μm
melt blown polypropylene over 0.45 μm polypropylene membrane. Lysate was filtered into
a Greiner 96-well Deepwell Plate by centrifugation at 2000 rcf for 5 min. Filtrate was
evaporated to dryness under nitrogen gas and then reconstituted in 200 μl of sample diluent
(60:40 methanol:10 mM ammonium acetate [native pH]) and mixed for 15 min on the plate
shaker at 500 rpm. Reconstituted samples were transferred to a Whatman 96-well Unifilter
Plate with 0.45 μm polyvinylidene fluoride (PVDF) membrane and collected into a Costar
3956 96-well plate (Corning, Corning NY) by centrifugation at 2000 rcf for 5 min. The 96-
well plate was sealed with a silicone capmat prior to LC-MS/MS analysis. Liquid handling
during these procedures was accomplished using a Hamilton Microlab® STAR 12-pipetting
channel liquid handling workstation and Tomtec Quadra 96® 320 96-well simultaneous
pipetting workstation.
Sample preparation for LC-MS/MS analysis of BAs in culture medium
A volume of 300 μl of 100% methanol containing 25 nM d4-TCA as an internal standard
was added to a well within a Millipore 96-well MultiScreen Deep Well Solvinert filter plate.
This was followed by the addition of 100 μl of medium study sample and mixing on the
plate shaker at a speed of 500 rpm for 15 min. Following protein precipitation, the filter
plate was stacked on a deep well plate and centrifuged at 2000 × rcf for 5 minutes. Filtrate
was evaporated to dryness under nitrogen gas and reconstituted in 200 μl of sample diluent
(60:40 [v/v] methanol:10 mM ammonium acetate [native pH]) and mixed for 15 min on the
plate shaker at 500 rpm. Reconstituted samples were transferred to a Whatman 96-well
Unifilter Plate with 0.45 μm PVDF membrane and collected into a Costar 3956 96-well
plate (Corning, Corning NY) by centrifugation at 2000 × rcf for 5 min. The 96-well plate
was sealed with a silicone capmat prior to LC-MS/MS analysis. Liquid handling during
these procedures was accomplished using a Hamilton Microlab® STAR 12-pipetting
channel liquid handling workstation and Tomtec Quadra 96® 320 96-well simultaneous
pipetting workstation.
Endogenous BAs were measured using standard curves prepared with stable isotope
equivalents. Ten microliters of deuterated BAs (d8-TCA, d4-GCA, d4-TCDCA, d4-GCDCA)
solutions in methanol were added to 300 μl of 100% methanol containing 25 nM internal
standard within a Millipore 96-well filter plate. The final concentration range for rat culture
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medium analysis was 0.5 - 50 pmol/100 μl for each deuterated BA, and for human culture
analysis was 0.5 – 50 pmol/100 μl for d8-TCA, d4-TCDCA, and d4-GCDCA, and 100 –
5000 pmol/100 μl for d4-GCA. This was followed by the addition of 90 μl cell culture
medium and then mixing on the plate shaker for 15 min. Further processing of medium
standard was completed as described for medium study samples described above.
LC-MS/MS analysis
Chromatographic separation of a 10 μl sample injection volume was accomplished using a
Shimadzu binary high-performance liquid chromatography system (Columbia, MD)
incorporating LC-10ADvp pumps, a CTO-10Avp oven, a Shimadzu HTc 96-well
autosampler, and a Thermo Scientific Hypersil GOLD C18 column (100 × 1.0 mm, 3 μm)
with matching guard and pre-column filter. The mobile phase was initially 70% [60% 0.5
mM ammonium acetate (native pH):40% methanol]:30% [20% 0.5 mM ammonium acetate
(native pH):80% methanol]. From 2-15 min, the gradient was ramped to 100% [20% 0.5
mM ammonium acetate (native pH):80% methanol], then stepped back to initial conditions
over 1 min. The flow rate through the column was 50 μl/min, and the column was
maintained at 35°C. The autosampler was maintained at 4°C and rinsed with 1500 μl of
50:50 (v/v) methanol:water after aspiration. Methanol (10 μl/min) was added as a post-
column solvent to the MS. A Thermo Electron TSQ Quantum Discovery MAX (Thermo
Fisher Scientific) with an Ion Max ESI source in negative ion electrospray ionization mode
was used for tandem mass spectrometry. The scan type was selected reaction monitoring
(SRM). The transitions monitored at unit resolution are listed in Table 2. Results for
unknowns were calculated using a standard curve based on internal standard processing. To
assess assay variability, standards were measured at the beginning of each run and QCs were
measured at the middle and end of each run. In order to be considered an acceptable
analysis, values for standards and QCs typically back-calculated to within 20% of theoretical
values.
Both α- and β-TMCA have the same MS precursor and product negative ions as TCA, thus
the MS data for these taurine conjugates of MCA were collected in the same analytical run
as TCA. Because of the chromatographic separation utilized in this study, TCA was well
resolved from α- and β-TMCA, however, the stereoisomers α- and β-TMCA were not
separated from each other and were measured collectively (designated α/β TMCA). Because
of the equal molar MS response of α/β TMCA relative to TCA, and the high linear dynamic
range of the d8-TCA standard curve supporting measurement of TCA, α/β TMCA was
measured in both lysate and medium data sets utilizing an extrapolated version of the same
standard curve utilized for TCA measurement for unknown samples. Study samples could
not be analyzed for glycine conjugates of α- and β-MCA because analytical standards were
not available for these compounds.
Data Analysis
The amount of individual BAs per medium sample was measured in pmol/ml (nM) and
lysate samples were measured in pmol/well and scaled per mg protein using a representative
mean value of 0.9 mg protein per well of a six-well plate as measured using the Pierce
BCA™ Protein Assay Kit (Thermo Scientific, Rockford, IL); samples below the limit of
quantitation were assigned a proxy value of zero. Estimates for individual and total BA
concentrations were calculated based on the amount of the BA species measured in lysates
from cells+bile and cells, and estimates of hepatocyte intracellular volume and the number
of cells/well (6.83 μl cells/well for rat SCH, 6.79 μl cells/well for human) (Lee and Brouwer
2010). Concentrations of BAs in the culture medium were calculated using a volume of 1.5
ml/well. The biliary excretion index (BEI), which represents the percentage of accumulated
substrate that is excreted into bile canaliculi, was calculated using B-CLEAR® technology
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(Qualyst, Inc., Durham, NC) using the following equation: BEI =
[(Accumulationstandard buffer – Accumulationcalcium-free buffer)/Accumulation standard buffer] *
100% (Liu et al. 1999). Statistical analysis (two-way ANOVA with Bonferroni’s multiple
comparison test) was performed using GraphPad Prism 5.03. In all cases, a p value < 0.05
was required in order to be considered statistically significant.
Results
Determination of BAs in cells+bile and cells of untreated rat SCH over days in culture
Total BAs (sum of TCA, GCA, TCDCA, GCDCA, and α/β TMCA) were measured in cells
+bile and cells in rat SCH over days 1 to 4 of culture (Figure 1A). BAs in cells+bile and in
cells remained relatively constant over days 1 to 4; these data suggest that BAs do not
accumulate in the cells over days in culture. Unlike cells+bile and cells, both individual and
total BAs in the culture medium increased over days in culture (data not shown).
Immunoblot analysis indicated that Cyp7a1 protein expression was unchanged over days in
culture; expression on days 2, 3, and 4 was 96%, 90%, and 96%, respectively, of the
expression on day 1 (Figure 1B).
Accumulation of BAs in cells+bile, cells, and medium of rat and human SCH
Experiments were designed to compare the BA pools between rat and human SCH. Figures
2 – 5 show the accumulation of TCA, GCA, TCDCA, and GCDCA, respectively, in cells
+bile, cells, and medium of rat and human SCH following 24 h treatment with vehicle
starting day 3 to and ending day 4. In addition, accumulation of α/β TMCA in rat SCH is
shown in Figure 6. Accumulation of TCA in cells+bile, cells, and medium in rat SCH was
about 3.2-fold, 1.8-fold, and 18.0-fold higher, respectively, than in human SCH (Figure 2).
In contrast, accumulation of GCA in cells+bile, cells, and medium in human SCH was
several orders of magnitude greater in human than in rat (Figure 3). The trends observed
with TCA and GCA also were observed with TCDCA and GCDCA. Accumulation of
TCDCA in cells+bile, cells, and medium in rat SCH was about 2.7-fold, 2.3-fold, and 14.6-
fold higher, respectively, than in human SCH (Figure 4). GCDCA was the most abundant
BA in human SCH; accumulation of GCDCA in cells+bile, cells, and medium in human
SCH was 584-fold, 766-fold, and 102-fold higher, respectively, than in rat SCH (Figure 5).
Accumulation of α/β TMCA in rat SCH was extensive, comprising the majority of the BAs
measured in cells+bile, cells, and medium (Figure 6). Treatment with TRO for 24 h had no
statistically significant effect on intracellular accumulation of any of the BAs.
Accumulation of total BAs (the sum of all BAs measured) in human SCH and in rat SCH
(which includes α/β TMCA) are shown in Figure 7. Total accumulation of BAs in CTL cells
+bile, cells, and medium were approximately 3.4, 2.9, and 8.3-fold greater in human than in
rat. Overall, > 99% of BAs in rat SCH were conjugated to taurine, while in human SCH, >
99% of BAs were conjugated to glycine. The biliary excretion index (BEI) for each BA
species, as well as estimates for individual and total BA concentrations in cells+bile and
cells were calculated as described in Materials and Methods (Tables 3 and 4). The rank
order of the mean BEI values of individual BAs from highest to lowest in rat SCH was TCA
> TCDCA > GCA > GCDCA > α/β TMCA. The rank order of intracellular concentrations
of the individual BAs in rat were α/β TMCA >> TCDCA > TCA > GCDCA > GCA; the
rank order of medium concentrations was α/β TMCA > TCA > TCDCA > GCA > GCDCA.
In human, the rank order of BEIs was TCA > GCA > GCDCA > TCDCA. The rank order of
intracellular concentrations in human SCH was GCDCA > GCA > TCDCA > TCA, while
the rank order of medium concentrations was GCA >> GCDCA > TCA > TCDCA. BA
concentrations in the bile compartment were not estimated because the volume of the bile
canalicular spaces is not known.
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BAs remained constant in cells+bile and cells of untreated rat SCH over days in culture
Initial experiments characterized the disposition of BAs over days in culture in the
intracellular and biliary compartments of rat SCH. Total BA mass in cells+bile and cells
remained constant over time. Analysis of BAs in the culture medium indicated that BAs
increased over days, which may be attributed to increased BA synthesis and efflux, although
immunoblot analysis indicated that protein expression of Cyp7a1, the rate-limiting enzyme
in BA synthesis, remained stable over days in culture. The current studies measured BAs
only in rat SCH through day 4; other investigators have reported that CYP7A1 mRNA
increased several-fold from day 2 to day 4 in human hepatocytes cultured on a single layer
of matrigel, suggesting increased BA synthesis capabilities (Ellis et al. 1998). Sauter et al.
reported that total BA efflux from human SCH into the culture medium remained relatively
constant from days 4-12 of culture (Sauter et al. 1996).
Species differences are evident in BA profiles of rat vs human SCH
BA profiles between rat and human SCH differed in two prominent ways. First, the total
mass of BAs was ~7-fold greater in human SCH than in rat SCH, even when including α/β
TMCA in rat, which is a rodent-specific BA. Conventionally-cultured human hepatocytes
reportedly exhibited greater capacity to synthesize BAs than conventionally-cultured rat
hepatocytes, even though BA synthesis in rat liver in vivo is 3- to 5-fold higher than in
human liver (Ellis et al. 1998); although variability was high in human SCH in these studies,
results were consistent with this observation. Variability was not unexpected; human plasma
concentrations of CA and CDCA varied by 103-115% and 62-84%, respectively (Ahlberg et
al. 1977; Tagliacozzi et al. 2003). In rodents, CDCA can be further hydroxylated to form
muricholic acid (MCA), which is then conjugated to glycine or to taurine to form
glycomuricholic acid (GMCA) or TMCA species (Botham and Boyd 1983). Analysis of α/β
TMCA in rat SCH suggested that the total mass of BAs measured when including this
abundant BA was still several-fold lower than in human SCH.
Second, taurine-conjugated BAs predominated in rat SCH, while glycine-conjugated BAs
predominated in human SCH. Taurine-conjugated BAs, particularly α/β TMCA, comprised
greater than 99% of BAs in rat SCH, consistent with reports that ~94-98% of BAs in rats are
conjugated to taurine (Alvaro et al. 1986; Mizuta et al. 1999; Pellicoro et al. 2007). In
human SCH, >99% of BAs were conjugated to glycine, and <1% were conjugated to
taurine. These values differ from previous reports of ~75% glycine conjugates and ~25%
taurine conjugates in human plasma and bile, but consistent with these previously reported
concentrations of BAs, GCDCA was the most abundant BA measured in human SCH
followed by GCA (Alvaro et al. 1986; Byrne et al. 2002; Tagliacozzi et al. 2003). One
explanation for decreased taurine conjugation of BAs in human SCH could be depletion of
available taurine; hepatic taurine concentrations are a major determinant of the proportion of
BAs conjugated with taurine versus glycine (Hardison and Proffitt 1977). Because glycine is
easily synthesized and not readily depleted in vivo, the concentration of available taurine
determines the amount of BAs conjugated to taurine (Gottfries et al. 1966). While both rat
and human SCH were exposed to the same culture conditions, rat hepatocytes were treated
on day 3 and assayed on day 4, whereas human hepatocytes were treated on day 6 and
assayed on day 7 due to delayed formation of bile canalicular networks in human SCH.
Intracellular and medium concentrations of BAs in rat and human SCH are comparable to
reported values
Concentrations of BAs were estimated in cells+bile and cells using estimates for cell
volume; BA concentrations in medium were based on a volume of 1.5 ml/well. Direct
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comparisons of intracellular concentrations of BAs between this study and other published
values are difficult; efflux of BAs into the culture medium is reported most commonly in in
vitro studies, and BAs measured in rat or human liver tissue likely also include residual BAs
from bile canaliculi within the tissue. Furthermore, individual BAs are not always measured.
In this study, the estimated concentration of total BAs measured (TCA + GCA + TCDCA +
GCDCA + α/β TMCA) on day 4 in the medium of rat SCH (1.16 ± 0.21 μM) was 8.3-fold
higher than the published concentration of total CA species + CDCA species of 0.14 ± 0.03
μM in the medium of rat conventionally-cultured hepatocytes (Ellis et al. 1998). This may
reflect a greater capacity of hepatocytes cultured in sandwich-configuration to synthesize
and efflux BAs. Dunn et al. (1991) quantified total BAs in the medium of rat SCH by
measuring the conversion of 3α-hydroxy bile acids into 3-oxo bile acids catalyzed by 3α-
hydroxysteroid dehydrogenase, based on the method of Mashige et al. (1981), and reported a
BA secretion rate of ~1.2 nmol/hr in 4 ml medium; this translates to a maximum
concentration of ~7 μM over a 24 h period (Dunn et al. 1991). The medium concentration of
BAs in human SCH in the present study (9.61 ± 6.36 μM), also was ~2.6-fold higher than
the published value of 3.68 ± 1.47 μM in the medium of human hepatocytes cultured in a
conventional monolayer (Ellis et al. 1998), but is in good agreement with the estimates of
~3-10 μM in human plasma (Ahlberg et al. 1977; Tagliacozzi et al. 2003). The intracellular
concentration of total BAs in humans in vivo is thought to be maintained at < 3 μM through
efficient uptake and efflux (Hofmann 1999), although intracellular BA concentrations can
reach 200 μM (Blitzer and Boyer 1982). The intracellular concentrations of total BAs in rat
SCH (66.9 ± 6.56 μM) and human SCH (183 ± 111 μM) were within these ranges.
Exposure to TRO for 24 h caused no significant effects on BA profiles in rat or human SCH
It has been hypothesized that the hepatotoxicity of TRO may be related to inhibition of
BSEP/Bsep and bile acid transport (reviewed in Masubuchi 2006). Several studies have
established that TRO and its major metabolite, troglitazone sulfate (TS), inhibit BA
transport (Preininger et al. 1999; Funk et al. 2001a; Funk et al. 2001b; Kemp et al. 2005).
Previous reports indicated that acute (10 min) exposure to TRO, at concentrations up to 10
μM, inhibited both NTCP/Ntcp- and OATP/Oatp-mediated uptake and BSEP/Bsep-
mediated canalicular excretion of exogenously administered [3H]TCA in vitro in both rat
and human hepatocytes, leading to decreased intracellular [3H]TCA accumulation (Kemp et
al. 2005; Marion et al. 2007; Ansede et al. 2010). Recently, however, Jemnitz et al.
preloaded [3H]TCA for 1 min into rat and human SCH and subsequently measured
[3H]TCA in cells + bile, cells, and medium following 10 min incubation with inhibitors;
using this method, 100 μM TRO decreased biliary excretion and increased intracellular
accumulation of [3H]TCA in both rat and human SCH without affecting basolateral efflux of
[3H]TCA into the medium (Jemnitz et al. 2010). When primary rat and human SCH were
incubated with 10 μM TRO for up to 120 min, TRO was metabolized rapidly and
extensively to TS, which accumulated within hepatocytes (Lee et al., 2010). Given that TS is
an even more potent inhibitor of BSEP/Bsep than parent TRO, it was hypothesized that
culturing SCH for 24 h with 10 μM TRO would alter the disposition of endogenous, newly
synthesized BAs, potentially causing the intracellular accumulation of one or more BAs.
However, results indicated that after 24 h exposure, TRO caused no significant changes in
the measured endogenous BA profiles in rat or human SCH. Further studies under different
exposure scenarios are required to fully characterize the time course of alterations in BA
disposition by inhibitors in SCH.
BAs may undergo basolateral efflux, and inhibition of NTCP/Ntcp- and OATP/Oatp-
mediated re-uptake of effluxed BAs by TRO or TS may help maintain low intracellular BA
concentrations. Compensatory mechanisms may also help maintain BA homeostasis in SCH.
Multidrug resistance-associated proteins MRP3 (ABCC3) and MRP4 (ABCC4) can excrete
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BAs from the hepatocyte across the basolateral membrane into sinusoidal blood (Rius et al.
2006; Rius et al. 2003; Zelcer et al. 2003a; Zelcer et al. 2003b). Both MRP3 and MRP4 are
induced in cholestasis, presumably as an adaptive response mechanism to compensate for
increased intracellular concentrations of BAs (Assem et al. 2004; Schuetz et al. 2001;
Zollner et al. 2003). Protein expression and/or membrane localization may increase in order
to facilitate BA efflux; for example, the canalicular transport proteins P-glycoprotein (P-gp),
BSEP, and MRP2 reside inside intracellular compartments and are capable of trafficking,
within minutes, to the canalicular membrane when the demand for BA and organic anion
efflux is increased (reviewed in Kipp and Arias 2002). Rapid membrane insertion of
transport proteins allows faster up-regulation of transport capability than is possible through
increased protein synthesis; therefore, increased membrane trafficking of transport proteins
from cytosolic vesicular compartments may increase BA efflux.
Estimations of intracellular and medium concentrations are possible using B-CLEAR®
technology
Data concerning the intracellular concentrations of xenobiotics (drugs, toxins, etc.) at the
target organ or tissue often are limited, especially in human studies. However, intracellular
concentrations may be a critical determinant of efficacy and/or toxicity. These results
indicate that the rat and human SCH models can be advantageous for determining the
cellular and biliary disposition of BAs, in addition to xenobiotics, since it is possible to
measure BAs in the cells+bile, cells, and medium compartments directly, and the bile
compartment indirectly. However, decreased expression of NTCP/Ntcp following isolation
and culture of hepatocytes may affect the disposition of BAs over time in culture. Also,
species differences exist in the time required for bile canaliculi formation, which indicates
that rat and human SCH may not be directly comparable at the same timepoints (reviewed in
Swift et al. 2010). Additionally, there are marked species differences in the BA profiles
between rat and human SCH as outlined in these studies. Differences in the BA pool
composition between rats and humans may influence the extent of toxicity of BA
accumulation. CDCA is more hydrophobic and, thus, cytotoxic than CA; glycine-conjugated
BAs are more toxic than taurine-conjugated BAs. The conversion of CDCA to MCA in
rodents increases its hydrophilicity and further decreases the toxicity of CDCA (reviewed in
Thomas et al. 2008). Thus, the predominance of TMCA in rat SCH compared to the
predominance of GCDCA in human SCH may differentially affect the potential for toxicity
caused by intracellular BA accumulation. Because individual BA species have different
affinities for BA transporters, and inhibitors can have differential effects on transport
kinetics based on species (Marion et al. 2011; Kis et al. 2009; Byrne et al. 2002; Gerloff et
al. 1998; Noe et al. 2001), it may be necessary to take these differences into consideration
when extrapolating from rat to human.
In conclusion, BA profiles in rat and human SCH were similar to those reported in the
literature in other in vitro models and in vivo, suggesting that SCH may be a promising
model to study the effects of xenobiotics on endogenous BA metabolism and disposition.
However, clear differences in the BA pool composition (i.e. taurine versus glycine
conjugation; the presence of MCA species in rodents) between rats and humans warrant
consideration when attempting to compare the hepatobiliary disposition of specific BAs
between species.
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>Sandwich-cultured hepatocytes (SCH) are commonly used to study hepatic transport.
>Endogenous bile acids were measured in rat and human SCH. >Bile acid profiles in
SCH were similar to those reported in vivo for each species. >The relative mass of
individual bile acids differed markedly between species. > 24-h troglitazone treatment
had no significant effect on intracellular accumulation of bile acids.
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Accumulation (pmol/mg protein) of total BAs (TCA, GCA, TCGCA, GCDCA, α/β TMCA)
in cells+bile (solid bars) and cells (open bars) in rat SCH over days 1 through 4 of culture.
Values represent mean ± range of duplicate determinations in n=2 experiments.
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Protein expression of Cyp7a1 in CTL rat SCH cell lysates over days 1 through 4 of culture;
β-actin served as the loading control. Same-day samples represent individual samples
collected from duplicate wells.
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Accumulation in pmol/mg protein (cells+bile and cells) and nM (medium) of TCA in cells
+bile (solid bars), cells (open bars), and medium (hatched bars) in rat and human SCH
following 24 h treatment with vehicle (0.1% DMSO). In CTL rat SCH, values represent the
mean ± SD of duplicate or triplicate measurements (cells+bile and cells) in n=4 experiments,
and mean ± SD of 3-6 measurements (medium) in n=3 experiments. In human SCH, values
represent mean ± SD of single or duplicate measurements (cells+bile and cells) and mean ±
SD of 2-6 measurements (medium) in n=4 experiments.
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Accumulation in pmol/mg protein (cells+bile and cells) and nM (medium) of GCA in cells
+bile (solid bars), cells (open bars), and medium (hatched bars) in rat and human SCH
following 24 h treatment with vehicle (0.1% DMSO). In CTL rat SCH, values represent the
mean ± SD of duplicate or triplicate measurements (cells+bile and cells) in n=4 experiments,
and mean ± SD of 3-6 measurements (medium) in n=3 experiments. In human SCH, values
represent mean ± SD of single or duplicate measurements (cells+bile and cells) and mean ±
SD of 2-6 measurements (medium) in n=4 experiments. Inset shows accumulation of GCA
in cells+bile, cells, and medium in rat SCH with the y-axis scaled for easier visualization.
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Accumulation in pmol/mg protein (cells+bile and cells) and nM (medium) of TCDCA in
cells+bile (solid bars), cells (open bars), and medium (hatched bars) in rat and human SCH
following 24 h treatment with vehicle (0.1% DMSO). In CTL rat SCH, values represent the
mean ± SD of duplicate or triplicate measurements (cells+bile and cells) in n=4 experiments,
and mean ± SD of 3-6 measurements (medium) in n=3 experiments. In human SCH, values
represent mean ± SD of single or duplicate measurements (cells+bile and cells) and mean ±
SD of 2-6 measurements (medium) in n=4 experiments.
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Accumulation in pmol/mg protein (cells+bile and cells) and nM (medium) of GCDCA in
cells+bile (solid bars), cells (open bars), and medium (hatched bars) in rat and human SCH
following 24 h treatment with vehicle (0.1% DMSO). In CTL rat SCH, values represent the
mean ± SD of duplicate or triplicate measurements (cells+bile and cells) in n=4 experiments,
and mean ± SD of 3-6 measurements (medium) in n=3 experiments. In human SCH, values
represent mean ± SD of single or duplicate measurements (cells+bile and cells) and mean ±
SD of 2-6 measurements (medium) in n=4 experiments. Inset shows accumulation of
GCDCA in cells+bile, cells, and medium in rat SCH with the y-axis scaled for easier
visualization.
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Accumulation in pmol/mg protein (cells+bile and cells) and nM (medium) of α/β TMCA
measured in cells+bile (solid bar), cells (open bar), and medium (hatched bar) in rat SCH
following 24 h treatment with vehicle (0.1% DMSO). Values represent the mean ± SD of
duplicate or triplicate measurements (cells+bile and cells) in n=4 experiments, and mean ±
SD of 3 or 6 measurements (medium) in n=3 experiments.
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Accumulation in pmol/mg protein (cells+bile and cells) and nM (medium) of total BAs
measured in cells+bile (solid bars), cells (open bars), and medium (hatched bars) in rat and
human SCH following 24 h treatment with vehicle (0.1% DMSO). Inset shows
accumulation of BAs in cells+bile, cells, and medium in rat SCH with the y-axis scaled for
easier visualization.
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Table 1
Demographic data for human liver donors.
Donor HU0803 HU1067 HU1184 HU1191
Age 42 61 73 19
Sex male male female male
Race Caucasian Caucasian Caucasian Caucasian
Height (in) 72 76 66 74
Weight (lb) 240 215 150 152
BMI (%) 32.6 26.2 24.2 19.5
Smoker no no no no
Alcohol Use rare no rare no
Serology not known not tested Hep B and Hep C: non-reactive
Hep B and Hep C: non-
reactive
HIV: not tested HIV: not tested
Medications not known Zantac 300 mg QD Hydrochlorithiazide 12.5mg QD none
Prilosec 20 mg BID Flagyl
Allegra 180 mg QD
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Table 2









TCA 515.7 7.5 514 124
d8-TCA 523.7 7.5 522 128
d4-TCA (IS) 519.7 7.5 518 124
TCDCA 499.7 10 498 80
d4-TCDCA 503.7 10 502 80
GCA 465.6 7.5 464 74
d4-GCA 469.6 7.5 468 74
GCDCA 449.6 10 448 74
d4-GCDCA 453.6 10 452 74
α/β TMCA 515.7 4.0 514 124
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Table 3
BEI (% ± SD) and concentrations of individual BAs in cells+bile, cells, and medium in CTL (μM ± SD for
cells+bile, cells, and medium) and TRO-treated (μM ± SD for cells+bile and cells, μM ± range for medium)
rat SCH. Calculations assume a hepatocyte volume of 6.83 μl cells/well in a 6-well plate for rat SCH as
described in Materials and Methods.
Rat cells+bile cells medium BEI
TCA CTL 2.22 ± 0.964 0.698 ± 0.203 0.262 ± 0.113 64.7 ± 18.3
TCA TRO 2.17 ± 0.745 0.773 ± 0.195 0.265 ± 0.142 59.9 ± 23.2
GCA CTL 0.054 ± 0.078 0.005 ± 0.010 0.030 ± 0.022 40.2 ± 49.1
GCA TRO 0.086 ± 0.100 0.032 ± 0.029 0.031 ± 0.025 35.4 ± 35.9
TCDCA CTL 2.39 ± 1.50 1.54 ± 1.43 0.050 ± 0.049 43.0 ± 20.3
TCDCA TRO 1.64 ± 1.13 1.26 ± 1.17 0.051 ± 0.044 32.1 ± 21.3
GCDCA CTL 0.242 ± 0.182 0.134 ± 0.141 0.013 ± 0.015 37.0 ± 30.5
GCDCA TRO 0.197 ± 0.174 0.143 ± 0.134 0.012 ± 0.012 18.8 ± 18.6
α/β TMCA CTL 77.8 ± 25.9 62.0 ± 13.0 0.808 ± 0.452 20.2 ± 13.8
α/β TMCA TRO 92.0 ± 16.0 76.6 ± 15.8 0.532 ± 0.295 20.9 ± 18.2
Total CTL 82.7 ± 11.6 64.3 ± 5.85 1.16 ± 0.210
Total TRO 96.1 ± 7.17 78.8 ± 7.11 0.891 ± 0.148
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Table 4
BEI (% ± SD) and individual concentrations (μM ± SD) of BAs in cells+bile, cells, and medium in human
SCH. Calculations assume a hepatocyte volume of 6.79 μl cells/well in a 6-well plate for human SCH as
described in Materials and Methods.
Human cells+bile cells medium BEI (%)
TCA CTL 0.703 ± 0.408 0.391 ± 0.189 0.010 ± 0.010 41.7 ± 16.2
TCA TRO 0.334 ± 0.179 0.187 ± 0.141 0.008 ± 0.008 45.6 ± 39.7
GCA CTL 136 ± 112 78.7 ± 64.1 8.70 ± 12.7 40.4 ± 11.9
GCA TRO 59.0 ± 46.0 32.4 ± 26.9 6.59 ± 8.29 38.5 ± 26.0
TCDCA CTL 0.876 ± 0.249 0.666 ± 0.151 0.002 ± 0.003 21.8 ± 14.3
TCDCA TRO 0.469 ± 0.030 0.432 ± 0.061 0.003 ± 0.002 9.45 ± 12.3
GCDCA CTL 142 ± 130 104 ± 91.0 0.891 ± 1.23 24.2 ± 8.81
GCDCA TRO 73.8 ± 70.1 63.4 ± 62.4 0.706 ± 0.784 17.4 ± 18.2
Total CTL 281 ± 85.7 183 ± 55.6 9.61 ± 6.36
Total TRO 134 ± 41.9 96.5 ± 34.0 7.31 ± 4.17
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